JP2022526856A5 - - Google Patents

Info

Publication number
JP2022526856A5
JP2022526856A5 JP2021560665A JP2021560665A JP2022526856A5 JP 2022526856 A5 JP2022526856 A5 JP 2022526856A5 JP 2021560665 A JP2021560665 A JP 2021560665A JP 2021560665 A JP2021560665 A JP 2021560665A JP 2022526856 A5 JP2022526856 A5 JP 2022526856A5
Authority
JP
Japan
Prior art keywords
seq
egfr
group
car
antigen
Prior art date
Application number
JP2021560665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526856A (ja
JPWO2020210768A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027859 external-priority patent/WO2020210768A1/en
Publication of JP2022526856A publication Critical patent/JP2022526856A/ja
Publication of JPWO2020210768A5 publication Critical patent/JPWO2020210768A5/ja
Publication of JP2022526856A5 publication Critical patent/JP2022526856A5/ja
Priority to JP2025044320A priority Critical patent/JP2025102823A/ja
Pending legal-status Critical Current

Links

JP2021560665A 2019-04-12 2020-04-11 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 Pending JP2022526856A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044320A JP2025102823A (ja) 2019-04-12 2025-03-19 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833456P 2019-04-12 2019-04-12
US62/833,456 2019-04-12
US201962892343P 2019-08-27 2019-08-27
US62/892,343 2019-08-27
PCT/US2020/027859 WO2020210768A1 (en) 2019-04-12 2020-04-11 Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044320A Division JP2025102823A (ja) 2019-04-12 2025-03-19 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法

Publications (3)

Publication Number Publication Date
JP2022526856A JP2022526856A (ja) 2022-05-26
JPWO2020210768A5 JPWO2020210768A5 (https=) 2022-09-30
JP2022526856A5 true JP2022526856A5 (https=) 2022-09-30

Family

ID=72751475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021560665A Pending JP2022526856A (ja) 2019-04-12 2020-04-11 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法
JP2025044320A Pending JP2025102823A (ja) 2019-04-12 2025-03-19 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044320A Pending JP2025102823A (ja) 2019-04-12 2025-03-19 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法

Country Status (5)

Country Link
US (1) US20220184129A1 (https=)
EP (1) EP3952885A4 (https=)
JP (2) JP2022526856A (https=)
AU (1) AU2020272074A1 (https=)
WO (1) WO2020210768A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259648A4 (en) * 2020-12-08 2025-03-26 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric anti-EGFR antigen receptors
EP4344409A4 (en) * 2021-07-01 2025-05-21 Duke University D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same
US20240285757A1 (en) * 2021-08-06 2024-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing car t cell efficacy through the engineered secretion of c. perfringens neuraminidase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2013327136A1 (en) * 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP3447072A3 (en) * 2013-03-05 2019-05-22 Baylor College of Medicine Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014201378A1 (en) * 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
JP6682509B2 (ja) * 2014-05-14 2020-04-15 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
WO2017027291A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
SG11201805449PA (en) * 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
MY209117A (en) * 2016-04-15 2025-06-23 Novartis Ag Compositions and methods for selective protein expression
WO2017181101A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric alloantigen receptor t cells
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CN110564749B (zh) * 2018-06-05 2024-01-05 上海恒润达生生物科技股份有限公司 靶向egfr的嵌合抗原受体及其用途
US20230158071A1 (en) * 2018-12-07 2023-05-25 Crage Medical Co., Limited Tumor combined immunotherapy

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP7150880B2 (ja) 抗－ｂ７－ｈ３抗体およびその用途
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
US12258405B2 (en) CD3 antibody and pharmaceutical use thereof
KR102366682B1 (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2018532383A5 (https=)
CN112969476B (zh) 多特异性蛋白分子
CA3132078A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
CN110536903A (zh) 抗ox40抗体及其用途
JP2019536470A5 (https=)
JP2020537520A (ja) Ｃｄ１３７を標的とする抗体とその利用方法
CA3075969A1 (en) Multispecific antibody comprising cd137 binding domain and pdl1 binding domain
CN106699891A (zh) 一种抗pd‑l1 抗体、其药物组合物及其用途
JP7611931B2 (ja) ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法
JP2022526856A5 (https=)
JPWO2020227457A5 (https=)
JP7753401B2 (ja) ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック
JP2022512628A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
JPWO2020210768A5 (https=)
JPWO2021147829A5 (https=)
JPWO2022217019A5 (https=)
JPWO2022072601A5 (https=)
RU2802272C2 (ru) Антитело к cd3 и его фармацевтическое применение
JPWO2023004326A5 (https=)
WO2024191322A1 (en) Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof